ATRX and cancer: Of the 186 patients without germline P/LP variants and available cancer genomes–exomes, 41/186 patients had a somatic variant in the DNA damage response pathway (ATRX, ATM, PPM1D, POLE) and 21/186 had a variant in the MAPK-ERK pathway (BRAF, NF1, PTPN11, MAPK12).